trending Market Intelligence /marketintelligence/en/news-insights/trending/p_cAanHs8zJNHg0b7B0rEA2 content esgSubNav
In This List

ImmunoGen plans common stock offering

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


ImmunoGen plans common stock offering

ImmunoGen Inc. plans to offer and sell 13 million common shares in an underwritten public offering.

The company plans to grant underwriters an option to buy up to an additional 15% of the shares offered.

Net proceeds will be used to fund the company's operations, including research and development activities, clinical trial activities, manufacturing and supply of drug substance and drug products, commercialization preparation, acquisitions of new technologies, capital expenditures and working capital.

Jefferies, Leerink Partners and RBC Capital Markets are acting as joint book-running managers for the proposed offering. Canaccord Genuity is acting as co-manager for the proposed offering.